160 related articles for article (PubMed ID: 38383439)
1. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Mol Cancer; 2024 Feb; 23(1):40. PubMed ID: 38383439
[TBL] [Abstract][Full Text] [Related]
2. The therapeutically actionable long non-coding RNA '
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Res Sq; 2023 Dec; ():. PubMed ID: 38077055
[TBL] [Abstract][Full Text] [Related]
3. Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.
Feichtenschlager V; Zheng YJ; Ho W; Chen L; Callanan C; Chen C; Lee A; Ortiz J; Rappersberger K; Ortiz-Urda S
Oncotarget; 2023 May; 14():543-560. PubMed ID: 37235843
[TBL] [Abstract][Full Text] [Related]
4. Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors.
Lobos-González L; Silva V; Araya M; Restovic F; Echenique J; Oliveira-Cruz L; Fitzpatrick C; Briones M; Villegas J; Villota C; Vidaurre S; Borgna V; Socias M; Valenzuela S; Lopez C; Socias T; Varas M; Díaz J; Burzio LO; Burzio VA
Oncotarget; 2016 Sep; 7(36):58331-58350. PubMed ID: 27507060
[TBL] [Abstract][Full Text] [Related]
5. The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.
Cardoso C; Serafim RB; Kawakami A; Gonçalves Pereira C; Roszik J; Valente V; Vazquez VL; Fisher DE; Espreafico EM
Pigment Cell Melanoma Res; 2019 Mar; 32(2):303-314. PubMed ID: 30457212
[TBL] [Abstract][Full Text] [Related]
6. GAB2 induces tumor angiogenesis in NRAS-driven melanoma.
Yang Y; Wu J; Demir A; Castillo-Martin M; Melamed RD; Zhang G; Fukunaga-Kanabis M; Perez-Lorenzo R; Zheng B; Silvers DN; Brunner G; Wang S; Rabadan R; Cordon-Cardo C; Celebi JT
Oncogene; 2013 Aug; 32(31):3627-37. PubMed ID: 22926523
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
[TBL] [Abstract][Full Text] [Related]
8. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways.
Liu S; Gao G; Yan D; Chen X; Yao X; Guo S; Li G; Zhao Y
Cancer Med; 2017 Apr; 6(4):819-833. PubMed ID: 28332309
[TBL] [Abstract][Full Text] [Related]
9. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.
Sanlorenzo M; Vujic I; Esteve-Puig R; Lai K; Vujic M; Lin K; Posch C; Dimon M; Moy A; Zekhtser M; Johnston K; Gho D; Ho W; Gajjala A; Oses Prieto J; Burlingame A; Daud A; Rappersberger K; Ortiz-Urda S
Sci Rep; 2018 Jul; 8(1):10902. PubMed ID: 30026510
[TBL] [Abstract][Full Text] [Related]
10. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
11. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
12. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
15. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.
Qian L; Chen K; Wang C; Chen Z; Meng Z; Wang P
Clin Cancer Res; 2020 Jul; 26(13):3408-3419. PubMed ID: 32156748
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Clinically Used Octenidine as
Chen XC; Tang GX; Dai J; Dai LT; Wu TY; Li WW; Ou TM; Huang ZS; Tan JH; Chen SB
J Med Chem; 2023 Apr; 66(7):5171-5184. PubMed ID: 36961300
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of lncRNAs and predicted target genes in normal mouse melanocytes and B16 cells.
Ji K; Zhang J; Fan R; Yang S; Dong C
Exp Dermatol; 2018 Nov; 27(11):1230-1236. PubMed ID: 30099777
[TBL] [Abstract][Full Text] [Related]
19. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
20. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
